Stocks · News reference

BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

Sep 10, 2026, 3:27 PMBenzinga Newsdesk

BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 9, 2026, 11:48 AMBenzinga Newsdesk
Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2
Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced
SER
SEC EDGARSep 9, 2026, 11:43 AMSEC EDGAR
8-K filing — Serina Therapeutics, Inc. (SER)
Filed: 2026-09-09 AccNo: 0001708599-26-000054 Size: 168 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
SER
BenzingaAug 24, 2026, 9:32 PMBenzinga Newsdesk
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
-SEC Filing
SER